Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed EBITDA Margin for 6 consecutive years, with 1558.58% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 460213.0% year-over-year to 1558.58%, compared with a TTM value of 290.49% through Sep 2025, up 201449.0%, and an annual FY2024 reading of 1440.5%, changed N/A over the prior year.
  • EBITDA Margin was 1558.58% for Q3 2025 at X4 Pharmaceuticals, down from 1329.55% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 12629.31% in Q2 2024 and bottomed at 6160.71% in Q3 2024.
  • Average EBITDA Margin over 4 years is 1236.88%, with a median of 2107.76% recorded in 2022.
  • The sharpest move saw EBITDA Margin skyrocketed 1038148bps in 2024, then plummeted -1395886bps in 2025.
  • Year by year, EBITDA Margin stood at 2235.75% in 2022, then rose by 1bps to 2247.82% in 2023, then tumbled by -206bps to 2381.0% in 2024, then surged by 35bps to 1558.58% in 2025.
  • Business Quant data shows EBITDA Margin for XFOR at 1558.58% in Q3 2025, 1329.55% in Q2 2025, and 32.78% in Q1 2025.